Brief Communication | Published:

PDZ binding of TARPγ-8 controls synaptic transmission but not synaptic plasticity

Nature Neuroscience volume 14, pages 14101412 (2011) | Download Citation

Abstract

The reduction in synaptic transmission and plasticity in mice lacking the hippocampus-enriched AMPA receptor (AMPAR) auxiliary subunit TARPγ-8 could be a result of a reduction in AMPAR expression or of the direct action of γ-8. We generated TARPγ-8Δ4 knock-in mice lacking the C-terminal PDZ ligand. We found that synaptic transmission and AMPARs were reduced in the mutant mice, but extrasynaptic AMPAR expression and long-term potentiation (LTP) were unaltered. Our findings suggest that there are distinct TARP-dependent mechanisms for synaptic transmission and LTP.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Neuron 70, 178–199 (2011).

  2. 2.

    et al. J. Neurosci. 19, 6027–6036 (1999).

  3. 3.

    et al. Nat. Neurosci. 8, 1525–1533 (2005).

  4. 4.

    et al. Eur. J. Neurosci. 24, 2177–2190 (2006).

  5. 5.

    et al. Science 284, 1805–1811 (1999).

  6. 6.

    et al. Nature 408, 936–943 (2000).

  7. 7.

    et al. Proc. Natl. Acad. Sci. USA 99, 13902–13907 (2002).

  8. 8.

    & Proc. Natl. Acad. Sci. USA 106, 11348–11351 (2009).

  9. 9.

    et al. Neurosci. Res. 55, 45–53 (2006).

  10. 10.

    , , & J. Neurosci. 23, 5503–5506 (2003).

  11. 11.

    & J. Neurosci. 24, 916–927 (2004).

  12. 12.

    et al. Neuron 57, 248–262 (2008).

  13. 13.

    et al. Neuron 68, 1082–1096 (2010).

  14. 14.

    et al. Neuron 67, 239–252 (2010).

Download references

Acknowledgements

We thank R. Nicoll (University of California, San Francisco) for providing the γ-8−/− mouse. The monoclonal antibody to SynDIG1 was developed by and/or obtained from the UC Davis/US National Institutes of Health NeuroMab. This work is supported by grants from the National Institute of Mental Health (MH077939 to S.T.) and from the US National Institutes of Health (NS050570 and NS065251 to J.A.K.).

Author information

Author notes

    • Akio Sumioka
    •  & Travis E Brown

    These authors contributed equally to this work.

Affiliations

  1. Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Akio Sumioka
    •  & Susumu Tomita
  2. Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Akio Sumioka
    •  & Susumu Tomita
  3. Depatment of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, Rhode Island, USA.

    • Travis E Brown
    •  & Julie A Kauer
  4. Department of Neuroscience, Brown University, Providence, Rhode Island, USA.

    • Travis E Brown
    •  & Julie A Kauer
  5. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.

    • Akihiko S Kato
    •  & David S Bredt

Authors

  1. Search for Akio Sumioka in:

  2. Search for Travis E Brown in:

  3. Search for Akihiko S Kato in:

  4. Search for David S Bredt in:

  5. Search for Julie A Kauer in:

  6. Search for Susumu Tomita in:

Contributions

S.T. and J.A.K. conceived the project and wrote the manuscript. A.S., T.E.B., A.S.K. D.S.B. and S.T. performed all of the experiments and analyzed the results. All of the authors contributed to the final version of the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Julie A Kauer or Susumu Tomita.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–7 and Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nn.2952

Further reading